EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues

Andrea Vallés-Martí iD, Richard R de Goeij-de Haas, Alex A Henneman, Sander R Piersma, Thang V Pham, Jaco C Knol, Joanne Verheij, Frederike Dijk, Hans Halfwerk, Elisa Giovannetti iD, Connie R Jiménez iD, Maarten F Bijlsma iD

Molecular Oncology · 2024

DOI: 10.1002/1878-0261.13625 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Oncology, 2024. Verfasst von Andrea Vallés-Martí und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Amsterdam University Medical Center, VU University, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 118 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KWF Kankerbestrijding, Nederlandse Organisatie voor Wetenschappelijk Onderzoek.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a limited number of known driver mutations but considerable cancer cell heterogeneity. Phosphoproteomics provides a direct read‐out of aberrant signaling and the resultant clinically relevant phenotype. Mass spectrometry (MS)‐based proteomics and phosphoproteomics were applied to 42 PDAC tumors. Data encompassed over 19 936 phosphoserine or phosphothreonine (pS/T; in 5412 phosphoproteins) and 1208 phosphotyrosine (pY; in 501 phosphoproteins) sites and a total of 3756 proteins. Proteome data identified three distinct subtypes with tumor intrinsic and stromal features. Subsequently, three phospho‐subtypes were apparent: two tumor intrinsic (Phos1/2) and one stromal (Phos3), resembling known PDAC molecular subtypes. Kinase activity was analyzed by the Integrative iNferred Kinase Activity (INKA) scoring. Phospho‐subtypes displayed differential phosphorylation signals and kinase activity, such as FGR and GSK3 activation in Phos1, SRC kinase family and EPHA2 in Phos2, and EGFR, INSR, MET, ABL1, HIPK1, JAK, and PRKCD in Phos3. Kinase activity analysis of an external PDAC cohort supported our findings and underscored the importance of PI3K/AKT and ERK pathways, among others. Interestingly, unfavorable patient prognosis correlated with higher RTK, PAK2, STK10, and CDK7 activity and high proliferation, whereas long survival was associated with MYLK and PTK6 activity, which was previously unknown. Subtype‐associated activity profiles can guide therapeutic combination approaches in tumor and stroma‐enriched tissues, and emphasize the critical role of parallel signaling pathways. In addition, kinase activity profiling identifies potential disease markers with prognostic significance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsHumansPrognosisFemaleMalePhosphorylationMiddle AgedProteomicsCell Line, TumorAged

Stichwörter der Autor:innen

kinase activitypancreatic ductal adenocarcinomapersonalized medicinephosphoproteome

Autor:innen und Institutionen

  • Department of Medical Oncology, Amsterdam University Medical Center, VU University, Amsterdam, The Netherlands.
  • OncoProteomics Laboratory, Cancer Center Amsterdam, The Netherlands.
  • Cancer Biology, Cancer Center Amsterdam, The Netherlands.
  • Pharmacology Laboratory, Cancer Center Amsterdam, The Netherlands.
  • Department of Pathology, Amsterdam University Medical Center, The Netherlands.
  • Cancer Pharmacology Lab, AIRC Start-Up Unit, Fondazione Pisana per la Scienza, San Giuliano Terme, Italy.

ORCID-Profile: Andrea Vallés-Martí, Elisa Giovannetti, Connie R Jiménez, Maarten F Bijlsma

Förderung

  • KWF Kankerbestrijding
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek

Zitieren

APA

Vallés-Martí, A., de Goeij-de Haas, R. R., Henneman, A. A., Piersma, S. R., Pham, T. V., Knol, J. C., Verheij, J., Dijk, F., Halfwerk, H., Giovannetti, E., Jiménez, C. R., & Bijlsma, M. F. (2024). Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues. Molecular Oncology. https://doi.org/10.1002/1878-0261.13625

Vancouver

Vallés-Martí A, de Goeij-de Haas RR, Henneman AA, Piersma SR, Pham TV, Knol JC, et al. Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues. Molecular Oncology. 2024. doi:10.1002/1878-0261.13625

BibTeX
@article{VallsMart2024,
  author = {Vallés-Martí, Andrea and de Goeij-de Haas, Richard R and Henneman, Alex A and Piersma, Sander R and Pham, Thang V and Knol, Jaco C and Verheij, Joanne and Dijk, Frederike and Halfwerk, Hans and Giovannetti, Elisa and Jiménez, Connie R and Bijlsma, Maarten F},
  title = {Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues},
  journal = {Molecular Oncology},
  year = {2024},
  doi = {10.1002/1878-0261.13625}
}
Kostenlos starten →